Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.43 |
| ▸ | PDCD1LG2 | Q9BQ51 | 4/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 4/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6823963 | 0.83 | NISCH (0.40) | CD274PDCD1LG2NISCHADRA2AADRA2B | |
| SCHEMBL6824496 | 0.81 | NISCH (0.38) | CD274PDCD1LG2NISCH | |
| SCHEMBL6824005 | 0.80 | TAAR1 (0.42) | CD274PDCD1LG2NISCHADRA2AADRA2B | |
| SCHEMBL6824335 | 0.74 | NISCH (0.46) | NISCHALDH1A1 | |
| SCHEMBL6825141 | 0.68 | NISCH (0.46) | NISCH | |
| SCHEMBL2257985 | 0.66 | NISCH (0.51) | CD274PDCD1LG2NISCHKCNH2 | |
| SCHEMBL11156503 | 0.66 | NISCH (0.51) | CD274PDCD1LG2NISCHKCNH2 | |
| SCHEMBL8194659 | 0.65 | NISCH (0.58) | CD274PDCD1LG2NISCHADRA2AADRA2B | |
| SCHEMBL14246838 | 0.65 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL23949063 | 0.65 | CD274 (0.62) | CD274PDCD1LG2NISCHPDCD1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | TAKEUCHI KUMIKO (US) | 2004-01-15 | — | — | US | disclosed |
| EP-0924209-B1 | Hypoglycemic imidazoline compounds | LILLY CO ELI (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1266897-A2 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6410562-B1 | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY | 2002-06-25 | — | — | US | disclosed |
| WO-1999032482-A1 | HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0924209-A1 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | GPR119, IAPP, GLP1R | CD274 4124/4885PDCD1LG2 4073/4885NISCH 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.